Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Current and future perspectives of liquid biopsies in genomics-driven oncology.

Heitzer E, Haque IS, Roberts CES, Speicher MR.

Nat Rev Genet. 2018 Nov 8. doi: 10.1038/s41576-018-0071-5. [Epub ahead of print] Review.

PMID:
30410101
2.

One size does not fit all: Size-based plasma DNA diagnostics.

Heitzer E, Speicher MR.

Sci Transl Med. 2018 Nov 7;10(466). pii: eaav3873. doi: 10.1126/scitranslmed.aav3873. Review.

PMID:
30404860
3.

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia.

Prochazka KT, Pregartner G, Rücker FG, Heitzer E, Pabst G, Wölfler A, Zebisch A, Berghold A, Döhner K, Sill H.

Haematologica. 2018 Oct 11. pii: haematol.2018.205013. doi: 10.3324/haematol.2018.205013. [Epub ahead of print]

4.

The potential of liquid biopsies for the early detection of cancer.

Heitzer E, Perakis S, Geigl JB, Speicher MR.

NPJ Precis Oncol. 2017 Oct 17;1(1):36. doi: 10.1038/s41698-017-0039-5. eCollection 2017. Review.

5.

Characterization of the endolysosomal system in human chordoma cell lines: is there a role of lysosomes in chemoresistance of this rare bone tumor?

Kolb-Lenz D, Fuchs R, Lohberger B, Heitzer E, Meditz K, Pernitsch D, Pritz E, Groselj-Strele A, Leithner A, Liegl-Atzwanger B, Rinner B.

Histochem Cell Biol. 2018 Jul;150(1):83-92. doi: 10.1007/s00418-018-1673-x. Epub 2018 May 3.

PMID:
29725750
6.

Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide.

Belic J, Graf R, Bauernhofer T, Cherkas Y, Ulz P, Waldispuehl-Geigl J, Perakis S, Gormley M, Patel J, Li W, Geigl JB, Smirnov D, Heitzer E, Gross M, Speicher MR.

Int J Cancer. 2018 Sep 1;143(5):1236-1248. doi: 10.1002/ijc.31397. Epub 2018 Apr 10.

7.

Digital Circulating Tumor Cell Analyses for Prostate Cancer Precision Oncology.

Heitzer E, Speicher MR.

Cancer Discov. 2018 Mar;8(3):269-271. doi: 10.1158/2159-8290.CD-18-0075.

PMID:
29500328
8.

Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.

Gaksch L, Kashofer K, Heitzer E, Quehenberger F, Daga S, Hofer S, Halbwedl I, Graf R, Krisper N, Hoefler G, Zebisch A, Sill H, Wölfler A.

Am J Hematol. 2018 Jan;93(1):23-30. doi: 10.1002/ajh.24922. Epub 2017 Oct 19.

PMID:
28960408
9.

G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1.

Hasenoehrl C, Feuersinger D, Sturm EM, Bärnthaler T, Heitzer E, Graf R, Grill M, Pichler M, Beck S, Butcher L, Thomas D, Ferreirós N, Schuligoi R, Schweiger C, Haybaeck J, Schicho R.

Int J Cancer. 2018 Jan 1;142(1):121-132. doi: 10.1002/ijc.31030. Epub 2017 Sep 21.

PMID:
28875496
10.

Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition.

Tiran V, Lindenmann J, Brcic L, Heitzer E, Stanzer S, Tabrizi-Wizsy NG, Stacher E, Stoeger H, Popper HH, Balic M, Dandachi N.

Sci Rep. 2017 Aug 30;7(1):10040. doi: 10.1038/s41598-017-09929-0.

11.

Single-Stranded DNA Library Preparation Does Not Preferentially Enrich Circulating Tumor DNA.

Moser T, Ulz P, Zhou Q, Perakis S, Geigl JB, Speicher MR, Heitzer E.

Clin Chem. 2017 Oct;63(10):1656-1659. doi: 10.1373/clinchem.2017.277988. Epub 2017 Aug 14. No abstract available.

12.

Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets.

Heitzer E, Sunitsch S, Gilg MM, Lohberger B, Rinner B, Kashofer K, Stündl N, Ulz P, Szkandera J, Leithner A, Liegl-Atzwanger B.

Mod Pathol. 2017 Dec;30(12):1698-1709. doi: 10.1038/modpathol.2017.94. Epub 2017 Aug 4.

PMID:
28776571
13.

miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5.

Stiegelbauer V, Vychytilova-Faltejskova P, Karbiener M, Pehserl AM, Reicher A, Resel M, Heitzer E, Ivan C, Bullock M, Ling H, Deutsch A, Wulf-Goldenberg A, Adiprasito JB, Stoeger H, Haybaeck J, Svoboda M, Stotz M, Hoefler G, Slaby O, Calin GA, Gerger A, Pichler M.

Clin Cancer Res. 2017 Sep 1;23(17):5255-5266. doi: 10.1158/1078-0432.CCR-17-0023. Epub 2017 May 22.

14.

MUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line.

Rinner B, Gandolfi G, Meditz K, Frisch MT, Wagner K, Ciarrocchi A, Torricelli F, Koivuniemi R, Niklander J, Liegl-Atzwanger B, Lohberger B, Heitzer E, Ghaffari-Tabrizi-Wizsy N, Zweytick D, Zalaudek I.

Sci Rep. 2017 May 18;7(1):2098. doi: 10.1038/s41598-017-02197-y.

15.

Patient monitoring through liquid biopsies using circulating tumor DNA.

Ulz P, Heitzer E, Geigl JB, Speicher MR.

Int J Cancer. 2017 Sep 1;141(5):887-896. doi: 10.1002/ijc.30759. Epub 2017 May 25. Review.

16.

Advances in Circulating Tumor DNA Analysis.

Perakis S, Auer M, Belic J, Heitzer E.

Adv Clin Chem. 2017;80:73-153. doi: 10.1016/bs.acc.2016.11.005. Epub 2017 Jan 3.

PMID:
28431643
17.

Genetic profiling of putative breast cancer stem cells from malignant pleural effusions.

Tiran V, Stanzer S, Heitzer E, Meilinger M, Rossmann C, Lax S, Tsybrovskyy O, Dandachi N, Balic M.

PLoS One. 2017 Apr 19;12(4):e0175223. doi: 10.1371/journal.pone.0175223. eCollection 2017.

18.

A novel mutation in ATRX associated with intellectual disability, syndromic features, and osteosarcoma.

Smolle MA, Heitzer E, Geigl JB, Al Kaissi A, Liegl-Atzwanger B, Seidel MG, Holzer LA, Leithner A.

Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26522. Epub 2017 Mar 30. No abstract available.

PMID:
28371197
19.

Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia.

Lal R, Lind K, Heitzer E, Ulz P, Aubell K, Kashofer K, Middeke JM, Thiede C, Schulz E, Rosenberger A, Hofer S, Feilhauer B, Rinner B, Svendova V, Schimek MG, Rücker FG, Hoefler G, Döhner K, Zebisch A, Wölfler A, Sill H.

Blood. 2017 May 4;129(18):2587-2591. doi: 10.1182/blood-2016-11-751008. Epub 2017 Mar 3. No abstract available.

20.

Academia Meets Industry.

Schäfer C, Paprotka T, Heitzer E, Eccleston M, Noe J, Holdenrieder S, Diehl F, Thierry A.

Adv Exp Med Biol. 2016;924:201-215.

PMID:
27753044
21.

mFast-SeqS as a Monitoring and Pre-screening Tool for Tumor-Specific Aneuploidy in Plasma DNA.

Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S, Fischereder K, Petru E, Bauernhofer T, Geigl JB, Speicher MR, Heitzer E.

Adv Exp Med Biol. 2016;924:147-155.

PMID:
27753036
22.

Inferring expressed genes by whole-genome sequencing of plasma DNA.

Ulz P, Thallinger GG, Auer M, Graf R, Kashofer K, Jahn SW, Abete L, Pristauz G, Petru E, Geigl JB, Heitzer E, Speicher MR.

Nat Genet. 2016 Oct;48(10):1273-8. doi: 10.1038/ng.3648. Epub 2016 Aug 29.

PMID:
27571261
23.

Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors.

Liegl-Atzwanger B, Heitzer E, Flicker K, Müller S, Ulz P, Saglam O, Tavassoli F, Devouassoux-Shisheboran M, Geigl J, Moinfar F.

Mod Pathol. 2016 Oct;29(10):1262-77. doi: 10.1038/modpathol.2016.107. Epub 2016 Jul 1.

24.

Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer.

Ulz P, Belic J, Graf R, Auer M, Lafer I, Fischereder K, Webersinke G, Pummer K, Augustin H, Pichler M, Hoefler G, Bauernhofer T, Geigl JB, Heitzer E, Speicher MR.

Nat Commun. 2016 Jun 22;7:12008. doi: 10.1038/ncomms12008.

25.

Establishment of clival chordoma cell line MUG-CC1 and lymphoblastoid cells as a model for potential new treatment strategies.

Gellner V, Tomazic PV, Lohberger B, Meditz K, Heitzer E, Mokry M, Koele W, Leithner A, Liegl-Atzwanger B, Rinner B.

Sci Rep. 2016 Apr 13;6:24195. doi: 10.1038/srep24195.

26.

Lysyl oxidase-like 2 promoter hypermethylation in mid-dermal elastolysis.

Gambichler T, Skrygan M, Reininghaus L, Schulze HJ, Schaller J, Hessam S, Colato C, Girolomoni G, Heitzer E.

Br J Dermatol. 2016 Dec;175(6):1354-1356. doi: 10.1111/bjd.14666. Epub 2016 Aug 17. No abstract available.

PMID:
27062057
27.

Co-occurrence of MYC amplification and TP53 mutations in human cancer.

Ulz P, Heitzer E, Speicher MR.

Nat Genet. 2016 Feb;48(2):104-6. doi: 10.1038/ng.3468. No abstract available.

PMID:
26813759
28.

Non-invasive detection of genome-wide somatic copy number alterations by liquid biopsies.

Heitzer E, Ulz P, Geigl JB, Speicher MR.

Mol Oncol. 2016 Mar;10(3):494-502. doi: 10.1016/j.molonc.2015.12.004. Epub 2015 Dec 17. Review.

29.

Detection of Circulating Tumor DNA in the Blood of Cancer Patients: An Important Tool in Cancer Chemoprevention.

Ulz P, Auer M, Heitzer E.

Methods Mol Biol. 2016;1379:45-68. doi: 10.1007/978-1-4939-3191-0_5.

PMID:
26608289
30.

POLE mutations in families predisposed to cutaneous melanoma.

Aoude LG, Heitzer E, Johansson P, Gartside M, Wadt K, Pritchard AL, Palmer JM, Symmons J, Gerdes AM, Montgomery GW, Martin NG, Tomlinson I, Kearsey S, Hayward NK.

Fam Cancer. 2015 Dec;14(4):621-8. doi: 10.1007/s10689-015-9826-8.

PMID:
26251183
31.

Rapid Identification of Plasma DNA Samples with Increased ctDNA Levels by a Modified FAST-SeqS Approach.

Belic J, Koch M, Ulz P, Auer M, Gerhalter T, Mohan S, Fischereder K, Petru E, Bauernhofer T, Geigl JB, Speicher MR, Heitzer E.

Clin Chem. 2015 Jun;61(6):838-49. doi: 10.1373/clinchem.2014.234286. Epub 2015 Apr 20.

32.

Circulating tumor DNA as a liquid biopsy for cancer.

Heitzer E, Ulz P, Geigl JB.

Clin Chem. 2015 Jan;61(1):112-23. doi: 10.1373/clinchem.2014.222679. Epub 2014 Nov 11. Review.

33.

Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X.

Schulz E, Klampfl P, Holzapfel S, Janecke AR, Ulz P, Renner W, Kashofer K, Nojima S, Leitner A, Zebisch A, Wölfler A, Hofer S, Gerger A, Lax S, Beham-Schmid C, Steinke V, Heitzer E, Geigl JB, Windpassinger C, Hoefler G, Speicher MR, Boland CR, Kumanogoh A, Sill H.

Nat Commun. 2014 Oct 13;5:5191. doi: 10.1038/ncomms6191.

34.

Preexisting TP53 mutation in therapy-related acute myeloid leukemia.

Schulz E, Kashofer K, Heitzer E, Mhatre KN, Speicher MR, Hoefler G, Sill H.

Ann Hematol. 2015 Mar;94(3):527-9. doi: 10.1007/s00277-014-2191-0. Epub 2014 Aug 20. No abstract available.

35.

The dynamic range of circulating tumor DNA in metastatic breast cancer.

Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C, Riethdorf S, Mauermann O, Lafer I, Pristauz G, Lax S, Pantel K, Geigl JB, Speicher MR.

Breast Cancer Res. 2014 Aug 9;16(4):421. doi: 10.1186/s13058-014-0421-y.

36.

Hematogenous dissemination of glioblastoma multiforme.

Müller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, Matschke J, Langer-Freitag S, Gasch C, Stoupiec M, Mauermann O, Peine S, Glatzel M, Speicher MR, Geigl JB, Westphal M, Pantel K, Riethdorf S.

Sci Transl Med. 2014 Jul 30;6(247):247ra101. doi: 10.1126/scitranslmed.3009095.

37.

Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.

Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, Pichler M, Gerger A, Eisner F, Hoefler G, Bauernhofer T, Geigl JB, Speicher MR.

PLoS Genet. 2014 Mar 27;10(3):e1004271. doi: 10.1371/journal.pgen.1004271. eCollection 2014 Mar.

38.

Replicative DNA polymerase mutations in cancer.

Heitzer E, Tomlinson I.

Curr Opin Genet Dev. 2014 Feb;24:107-13. doi: 10.1016/j.gde.2013.12.005. Epub 2014 Feb 26. Review.

39.

Multiplex genetic cancer testing identifies pathogenic mutations in TP53 and CDH1 in a patient with bilateral breast and endometrial adenocarcinoma.

Heitzer E, Lax S, Lafer I, Müller SM, Pristauz G, Ulz P, Jahn S, Högenauer C, Petru E, Speicher MR, Geigl JB.

BMC Med Genet. 2013 Dec 29;14:129. doi: 10.1186/1471-2350-14-129.

40.

Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N.

Mod Pathol. 2014 Jun;27(6):906-15. doi: 10.1038/modpathol.2013.204. Epub 2013 Dec 6.

41.

The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type.

Stadelmeyer E, Heitzer E, Resel M, Cerroni L, Wolf P, Dandachi N.

J Invest Dermatol. 2014 Feb;134(2):548-550. doi: 10.1038/jid.2013.338. Epub 2013 Aug 9. No abstract available.

42.

Circulating tumor cells and DNA as liquid biopsies.

Heitzer E, Auer M, Ulz P, Geigl JB, Speicher MR.

Genome Med. 2013 Aug 23;5(8):73. doi: 10.1186/gm477. eCollection 2013. Review.

43.

Genetic and epigenetic analysis of putative breast cancer stem cell models.

Balic M, Schwarzenbacher D, Stanzer S, Heitzer E, Auer M, Geigl JB, Cote RJ, Datar RH, Dandachi N.

BMC Cancer. 2013 Jul 24;13:358. doi: 10.1186/1471-2407-13-358.

44.

Single circulating tumor cell sequencing for monitoring.

Auer M, Heitzer E, Ulz P, Geigl JB, Speicher MR.

Oncotarget. 2013 Jun;4(6):812-3. No abstract available.

45.

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing.

Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K, Benezeder T, Auer M, Pischler C, Mannweiler S, Pichler M, Eisner F, Haeusler M, Riethdorf S, Pantel K, Samonigg H, Hoefler G, Augustin H, Geigl JB, Speicher MR.

Genome Med. 2013 Apr 5;5(4):30. doi: 10.1186/gm434. eCollection 2013.

46.

Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing.

Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Höfler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR.

Cancer Res. 2013 May 15;73(10):2965-75. doi: 10.1158/0008-5472.CAN-12-4140. Epub 2013 Mar 7.

47.

Depressed patients with incurable cancer: which depressive symptoms do they experience?

Brenne E, Loge JH, Kaasa S, Heitzer E, Knudsen AK, Wasteson E; European Palliative Care Research Collaborative (EPCRC).

Palliat Support Care. 2013 Dec;11(6):491-501. doi: 10.1017/S1478951512000909. Epub 2013 Feb 7. Erratum in: Palliat Support Care. 2013 Dec;11(6):535.

PMID:
23388067
48.

Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer.

Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, Lax S, Waldispuehl-Geigl J, Mauermann O, Mohan S, Pristauz G, Lackner C, Höfler G, Eisner F, Petru E, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR.

Int J Cancer. 2013 Jul 15;133(2):346-56. doi: 10.1002/ijc.28030. Epub 2013 Feb 13.

49.

Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study.

Rayment C, Hjermstad MJ, Aass N, Kaasa S, Caraceni A, Strasser F, Heitzer E, Fainsinger R, Bennett MI; European Palliative Care Research Collaborative (EPCRC).

Palliat Med. 2013 Sep;27(8):714-21. doi: 10.1177/0269216312464408. Epub 2012 Nov 21.

PMID:
23175513
50.

IL-7, IL-18, MCP-1, MIP1-β, and OPG as biomarkers for pain treatment response in patients with cancer.

Heitzer E, Sandner-Kiesling A, Schippinger W, Stohscheer I, Osprian I, Bitsche S, Eisner F, Verebes J, Hofmann G, Samonigg H.

Pain Physician. 2012 Nov-Dec;15(6):499-510.

Supplemental Content

Loading ...
Support Center